Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness

Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness

Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.Mat...

Full description

Bibliographic Details
Main Authors: N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. S. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2021-05-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
atrial fibrillation
atrial flutter
management
cardioversion
restoration of sinus rhythm
rhythm control
antiarrhythmic drugs
safety
effectiveness
Online Access:https://www.rpcardio.com/jour/article/view/2427

Internet

https://www.rpcardio.com/jour/article/view/2427

Similar Items